Cargando…
Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy
Autores principales: | Meesilpavikkai, Kornvalee, Dik, Willem A., Schrijver, Benjamin, van Helden‐Meeuwsen, Cornelia G., Versnel, Marjan A., van Hagen, P. Martin, Bijlsma, Emilia K., Ruivenkamp, Claudia A. L., Oele, Margreet J., Dalm, Virgil A. S. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593964/ https://www.ncbi.nlm.nih.gov/pubmed/30666809 http://dx.doi.org/10.1002/art.40805 |
Ejemplares similares
-
Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
por: Dell’Isola, Giovanni Battista, et al.
Publicado: (2023) -
Familial chilblain lupus due to a novel mutation in TREX1 associated with Aicardi–Goutie’res syndrome
por: Yi, Cuili, et al.
Publicado: (2020) -
Interferon-α and the calcifying microangiopathy in Aicardi–Goutières syndrome
por: Klok, Melanie D, et al.
Publicado: (2015) -
MRI Features Predictive of Aicardi-Goutieres Syndrome
por: Millichap, J. Gordon
Publicado: (2015) -
Aicardi–Goutières Syndrome: Brief Case Report
por: Moscote-Salazar, Luis Rafael, et al.
Publicado: (2018)